BDBM280768 US10030025, Compound 45-1::US10836768, Cpd no 45-2::US11731974, Compound 45-2::US9987274, Compound 45-2

SMILES C[C@H](F)c1noc(n1)-c1nnc2[C@@H](C)N(CCn12)C(=O)c1ccc(F)cc1

InChI Key InChIKey=UECKJWCZXJBAJH-UHFFFAOYSA-N

Data  13 KI  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 15 hits for monomerid = 280768   

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM280768(US10030025, Compound 45-1 | US9987274, Compound 45...)
Affinity DataIC50: 285nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM280768(US10030025, Compound 45-1 | US9987274, Compound 45...)
Affinity DataIC50: 148nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM280768(US10030025, Compound 45-1 | US9987274, Compound 45...)
Affinity DataKi:  83nMAssay Description:Human NK-3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2020
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM280768(US10030025, Compound 45-1 | US9987274, Compound 45...)
Affinity DataKi:  83nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM280768(US10030025, Compound 45-1 | US9987274, Compound 45...)
Affinity DataKi:  83nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist3 H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2023
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM280768(US10030025, Compound 45-1 | US9987274, Compound 45...)
Affinity DataKi:  83nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist3 H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2023
Entry Details
Go to US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM280768(US10030025, Compound 45-1 | US9987274, Compound 45...)
Affinity DataKi:  100nMpH: 7.4Assay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM280768(US10030025, Compound 45-1 | US9987274, Compound 45...)
Affinity DataKi: >3.00E+4nM ΔG°: >-6.17kcal/molepH: 7.4 T: 2°CAssay Description:The affinity of compounds of the invention for the NK-1 receptor was evaluated in CHO recombinant cells which express the human NK-1 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM280768(US10030025, Compound 45-1 | US9987274, Compound 45...)
Affinity DataKi: >3.00E+4nM ΔG°: >-6.17kcal/molepH: 7.4 T: 2°CAssay Description:The affinity of compounds of the invention for the NK-2 receptor was evaluated in CHO recombinant cells which express the human NK-2 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM280768(US10030025, Compound 45-1 | US9987274, Compound 45...)
Affinity DataKi: >3.00E+4nMAssay Description:Human NK-1: The affinity of compounds of the invention for the NK-1 receptor was evaluated in CHO recombinant cells which express the human NK-1 rece...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2020
Entry Details
Go to US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM280768(US10030025, Compound 45-1 | US9987274, Compound 45...)
Affinity DataKi: >3.00E+4nMAssay Description:Human NK-2 The affinity of compounds of the invention for the NK-2 receptor was evaluated in CHO recombinant cells which express the human NK-2 recep...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2020
Entry Details
Go to US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM280768(US10030025, Compound 45-1 | US9987274, Compound 45...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-1 receptor was evaluated in CHO recombinant cells which express the human NK-1 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
Go to US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM280768(US10030025, Compound 45-1 | US9987274, Compound 45...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-2 receptor was evaluated in CHO recombinant cells which express the human NK-2 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
Go to US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM280768(US10030025, Compound 45-1 | US9987274, Compound 45...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-1 receptor was evaluated in CHO recombinant cells which express the human NK-1 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2023
Entry Details
Go to US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM280768(US10030025, Compound 45-1 | US9987274, Compound 45...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-2 receptor was evaluated in CHO recombinant cells which express the human NK-2 receptor. Membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2023
Entry Details
Go to US Patent